Switching from the infliximab reference product to CT-P13 in patients with rheumatoid arthritis or ankylosing spondylitis: results of the PLANETAS and PLANETRA extension studies

CT-P13, also known by its brand names Remsima or Inflectra, is a biosimilar of the infliximab reference product (RP) Remicade. CT-P13 is approved in Europe, the US and elsewhere for use in all indications for which the RP is licensed, including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Approval of CT-P13 was partly based on findings from two pivotal clinical trials – PLANETAS and PLANETRA – which concluded that CT-P13 and the RP were highly comparable in terms of pharmacokinetics, efficacy, immunogenicity and safety in AS patients (PLANETAS) and RA patients (PLANETRA). Recently, data from extension phases of the original two clinical trials have been published in *Annals of the Rheumatic Diseases*. The data reported that it was possible to switch from the RP to CT-P13 without any detrimental effects on safety or efficacy. The studies also reported that CT-P13 was well tolerated and effective for up to two years in patients with RA and AS [1, 2].

Following the main 54-week randomized controlled trials during which patients with AS or RA received either the RP or CT-P13 [3, 4], patients were invited to enrol into 48-week extension studies. All patients who enrolled onto the extension studies were treated with CT-P13. Clinical efficacy and disease activity were assessed using a variety of different measurements, including Assessment of SpondyloArthritis international Society (ASAS) response rates (in patients with AS) and American College of Rheumatology (ACR) response rates (in patients with RA).

Three hundred and two patients with RA were enrolled and 301 were treated with CT-P13 in the PLANETRA extension study. Of these, 158 had received CT-P13 in the original study (‘maintenance group’) and 144 had received the RP (‘switch group’). One hundred and seventy-four patients with AS were treated with CT-P13. Clinical efficacy and disease activity were maintained over 2 years in the patients with RA and AS [1, 2], see Figure 1. In AS patients, ASAS20, ASAS40 and ASAS partial remission rates were also similar between the two groups, see Figure 2.

Clinical efficacy was maintained over 2 years in the patients with RA and AS who had received CT-P13 during both the original and extension studies. In patients with RA, the ACR20 response rate was 77.0% after 1 year of treatment with CT-P13, and 71.7% after 2 years of treatment. In patients with AS, the ASAS20 response rate was 70.5% after 1 year of treatment with CT-P13, and 80.7% after 2 years of treatment.

CT-P13 was well-tolerated during both extension studies, with a safety profile that was consistent with that of the RP [5, 6]. The proportion of patients developing anti-drug antibodies was also similar in the maintenance and switch groups in either extension study.

As patent expiration dates loom for many biological drugs, there is increasing interest in the development of biosimilar drugs. With tight healthcare budgets, many countries commonly recommend the least expensive drug be used for treating conditions such as RA and AS [7, 8]. With biosimilars typically being less expensive than originator biologicals [9], studies that examine whether patients can be switched from the originator biological to a biosimilar are vital to aid clinical decision-making. Switching to the biosimilar may lead to cost savings and increased access to treatment for more patients with these debilitating diseases.

**Competing interests:** The authors of research papers [1,2] declared that DHY and WP are consultants for Celltrion; for full details of all authors’ conflicts of interest, see the research papers [1, 2].

---

**Figure 1:** American College of Rheumatology (ACR) response rates at Week 102 for the CT-P13 maintenance group* and the switch group** in the PLANETRA extension study

* Patients in the maintenance group had received CT-P13 throughout the original 54-week PLANETRA study and continued to receive CT-P13 during the extension study.
** Patients in the switch group received the RP in the original 54-week PLANETRA study then switched to CT-P13 during the extension study.
CT-P13: Remsima or Inflectra; RP: Remicade.

**Figure 2:** Assessment of SpondyloArthritis international Society (ASAS) response rates at Week 102 for the CT-P13 maintenance group* and the switch group** in the PLANETAS extension study

* Patients in the maintenance group had received CT-P13 throughout the original 54-week PLANETAS study and continued to receive CT-P13 during the extension study.
** Patients in the switch group received the RP in the original 54-week PLANETAS study then switched to CT-P13 during the extension study.
CT-P13: Remsima or Inflectra; PR: partial remission; RP: Remicade.
References


Copyright © 2016 Pro Pharma Communications International